Hi @asarnesejr It’s hard to tell what future medical technology will come next. CAR-T therapy has really made a significant impact into curing some blood cancers. But there remain some mutations that pose challenges for that therapy. There are targeted therapies, biologic/genetic therapies, bone marrow transplants depending on what better fits the illness. Fortunately we have options and I’m assuming that will broaden as cancer research continues.
Regarding the DDX41 mutation, as we’ve talked about before in our discussions, according to data from studies, along with the conversations with @sherbs and @fortuitous, who also have the DDX41 mutation causing their AML, a stem cell transplant isn’t always the better option for treating AML with this mutation.
Some patients with this mutations may respond better with medications than with the bone marrow transplant. That’s why it’s critical to have an evaluation with a specialist who understands the complexities of this mutation.

I’d encourage you to look back at some of the first comments in this discussion by clicking the box that says #1. You’ll find links to the conversations that might be worth revisiting. ☺️